Hepatitis B is the major infectious occupational hazard to health workers. In some institutions, needle-stick injuries are the second most common occupational injury (after back injuries) [1] . Some needle-stick injuries to health workers occur with a source of blood or blood product from patients who are known to be hepatitis B surface antigen (HBsAg) positive at the time of the accident, and hepatitis B immune globulin (HBIG) administration has been officially recommended for these occurrences since 1977 [2] .
Most needle sticks, however, occur in situations where the HBsAg status of the source is unknown. In the absence of official guidelines, many hospitals devised protocols that often required extensive testing of both patients and staff. This resulted in data collection that had no bearing on clinical decisions and created excessive costs and delays in immunoglobulin administration that could compromise its efficacy. To remedy this situation, the Immunization Practices Advisory Committee (ACIP) of the U.S. Public Health Service issued revised guidelines on hepatitis B prophylaxis [3].
Reuler and Campbell, in a cost analysis of a needle stick protocol [4] , designed and conducted their study prior to these recommendations. Their conclusions are similar and lend support to this expert advisory group's guidelines.
However, two factors of this study are different from conditions in many United States hospitals previously studied. As such, some of the study's analyses and conclusions may not be applicable to other institutions.
The study institution has a 6% prevalence of anti-HBs (indicating previous exposure and current immunity) in its exposed employees. In needle sticks from known HBsAg-positive patients, screening all exposed employees for anti-HBs would cost more than the unnecessary second doses of HBIG that would be given without screening ($1300 versus $960) at this prevalence. However, many hospital staffs, especially in urban areas, have a much higher prevalence of anti-HBs, e.g., 14% in Phoenix [5] , 16% in Washington, D.C., 16% in Los Angeles, and 11% in Denver (manuscript in preparation). At a cost of $13 per test and $160 per HBIG dose, the breakeven point of testing is a prevalence of 8.125%. Nevertheless, even when antibody testing of exposed employees is done, if the source is known HBsAg-positive, the first dose of HBIG should be administered immediately, as was done by Reuler and Campbell, without waiting for these results.
The 4% (10/224) positivity of HBsAg rate for the patients involved in all the needle-stick exposures in the study hospital is high. In a general hospital population, the prevalence of HBsAg is closer to 1 % [6] . Among &dquo;high risk&dquo; groups, the rate averages 5 % (2% in drug abusers, 5 % in homosexuals, 12% in Indochinese refugees, etc.) [3] . The higher the HBsAg prevalence, the greater the risk of infectivity from each exposure and the greater the value of prophylactic HBIG in preventing cases of hepatitis B, but at a net cost. From our own studies, we estimate the cost per case of hepatitis averted if all exposed employees are treated prophylactically is $15,318 in a high risk population (prevalence of HBsAg = 5%) and $56,571 in a general hospital population (prevalence of HBsAg =1%). These calculations are available on request.
The authors recommend that all &dquo;high risk&dquo; patients be tested for HBsAg before, rather than after, they are involved as the &dquo;source&dquo; in an exposure, and that those found positive be listed. However, in even a high risk population with 5% prevalence of HBsAg, pre-needle-stick screening of patients results in 95% of tests being negative. In an Arizona hospital, only 18% of HBsAg-positive patients were known and a registry could produce a false sense of security [6] .
In addition, a &dquo;list&dquo; of HBsAg carriers is of limited value. Over 50% of reported hepatitis B cases deny belonging to identified &dquo;high risk&dquo; groups. The social and legal ramifications of some factors associated with high risk (sexual preference, use of illicit drugs, etc.) often make identification of these individuals difficult.
Reuler and Campbell take a commendable approach to investigating public health guidelines as appropriate to their setting. However, other hospital workers may wish to use different probabilities based on their own epidemiological data, national data sources, or other published studies. When decision analysis is employed thoroughly for the problem of needlestick exposures the ACIP guidelines are supported, but it is shown that passive prevention of hepatitis B incurs net costs.
The approach to the control of hepatitis B infeccion in health care and laboratory workers exposed to human blood or blood products will be altered by the availability of a new vaccine, shown to be safe and effective in preventing hepatitis B [7] .
